Table 1.
Univariate analysis of clinical and laboratory indicators and poor prognostic factors in lung cancer Patients.
| Variable | Survival group (N = 178) | Deceased group (N = 322) |
Standardized difference (95% CI) | P value |
|---|---|---|---|---|
| Laboratory Indicators | ||||
| Neutrophil Count (10^9/L) | 5.18 ± 2.70 | 5.66 ± 2.94 | 0.17 (−0.01, 0.35) | 0.071 |
| Platelet Count (10^9/L) | 245.18 ± 88.45 | 263.47 ± 113.03 | 0.18 (−0.00, 0.36) | 0.063 |
| Lymphocyte Count (10^9/L) | 1.41 ± 0.51 | 1.31 ± 0.54 | 0.20 (0.02, 0.38) | 0.034* |
| Serum Albumin (g/L) | 38.24 ± 4.09 | 35.82 ± 4.87 | 0.54 (0.35, 0.72) | < 0.001** |
| Serum Globulin (g/L) | 28.51 ± 4.80 | 30.55 ± 5.85 | 0.38 (0.20, 0.56) | < 0.001** |
| Monocyte Count (10^9/L)Log | −0.78 ± 0.45 | −0.67 ± 0.50 | 0.22 (0.04, 0.40) | 0.021* |
| Hemoglobin (g/L) | 133.81 ± 18.72 | 126.96 ± 20.46 | 0.35 (0.16, 0.53) | < 0.001** |
| Red Cell Distribution Width (FL) | 44.61 ± 27.40 | 47.55 ± 37.57 | 0.09 (−0.09, 0.27) | 0.360 |
| SII (Log) | 6.70 ± 0.82 | 6.94 ± 0.93 | 0.28 (0.09, 0.46) | 0.004** |
| PNI | 45.30 ± 4.97 | 42.35 ± 6.01 | 0.53 (0.35, 0.72) | < 0.001** |
| LMR | 3.26 ± 1.51 | 2.68 ± 1.42 | 0.39 (0.21, 0.58) | < 0.001** |
| PLR Log | 5.16 ± 0.52 | 5.32 ± 0.65 | 0.27 (0.08, 0.45) | 0.006** |
| HRR | 3.14 ± 0.54 | 2.89 ± 0.60 | 0.44 (0.25, 0.62) | < 0.001** |
| NLR | 4.40 ± 3.53 | 5.16 ± 4.12 | 0.20 (0.01, 0.38) | 0.039* |
| HALP | 33.83 ± 20.43 | 28.30 ± 19.31 | 0.28 (0.09, 0.46) | 0.003** |
| ALB/GLB | 1.38 ± 0.29 | 1.21 ± 0.29 | 0.58 (0.39, 0.76) | < 0.001** |
| Clinical Characteristics | ||||
| Age (years) | 58.28 ± 8.13 | 64.70 ± 9.84 | 0.71 (0.52, 0.90) | < 0.001** |
| BMI | 22.54 ± 3.06 | 22.29 ± 3.38 | 0.08 (−0.10, 0.26) | 0.401 |
| Gender | 0.15 (−0.03, 0.33) | 0.109 | ||
| Male | 117 (65.73%) | 233 (72.59%) | ||
| Female | 61 (34.27%) | 88 (27.41%) | ||
| Smoking History | 0.03 (−0.15, 0.21) | 0.735 | ||
| Yes | 116 (65.17%) | 214 (66.67%) | ||
| No | 62 (34.83%) | 107 (33.33%) | ||
| Diabetes | 0.02 (−0.16, 0.20) | 0.845 | ||
| Yes | 13 (7.30%) | 25 (7.79%) | ||
| No | 165 (92.70%) | 296 (92.21%) | ||
| Hypertension | 0.09 (−0.09, 0.28) | 0.310 | ||
| Yes | 43 (24.16%) | 65 (20.25%) | ||
| No | 135 (75.84%) | 256 (79.75%) | ||
| Tuberculosis | 0.02 (−0.16, 0.20) | 0.844 | ||
| Yes | 26 (14.61%) | 49 (15.26%) | ||
| No | 152 (85.39%) | 272 (84.74%) | ||
| Pathological Type | 0.23(0.04, 0.41) | 0.057 | ||
| Adenocarcinoma | 117 (65.73%) | 177 (55.14%) | ||
| Squamous Cell Carcinoma | 46 (25.84%) | 102 (31.78%) | ||
| Small Cell Carcinoma | 15 (8.43%) | 42 (13.08%) | ||
| Clinical Stage | 0.45(0.26, 0.64) | < 0.001** | ||
| Stage I | 38 (21.35%) | 24 (7.48%) | ||
| Stage II | 21 (11.80%) | 25 (7.79%) | ||
| Stage III | 39 (21.91%) | 86 (26.79%) | ||
| Stage IV | 80 (44.94%) | 186 (57.94%) | ||
| Differentiation | 0.37 (0.18, 0.55) | < 0.001** | ||
| Low | 146 (82.02%) | 301 (93.77%) | ||
| Moderate-High | 32 (17.98%) | 20 (6.23%) | ||
| Distant Metastasis | 0.27 (0.09, 0.45) | 0.004** | ||
| Yes | 81 (45.51%) | 189 (58.88%) | ||
| No | 97 (54.49%) | 132 (41.12%) | ||
| ECOG Performance Status | 0.51 (0.32, 0.70) | < 0.001** | ||
| 0–1 score | 152 (85.39%) | 205 (63.86%) | ||
| ≥ 2 score | 26 (14.61%) | 116 (36.14%) | ||
Note: 1.*P < 0.05, significant.2.**P < 0.01, highly significant.3.Standardized differences represent effect sizes, with 95% confidence intervals provided in parentheses.